KRP-101

a PPARalpha agonist that ameliorates insulin resistance in dogs fed a high-fat diet

Also Known As:

(2S)-2-((3-(N-((4-(4-fluorophenoxy)phenyl)methyl)carbamoyl)-4-methoxyphenyl)methyl)butanoic acid

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Dyslipidemias (Dyslipidemia) 05/01/2008 - "KRP-101 administration improved hyperglycemia and hyperinsulinemia as well as dyslipidemia in dogs fed a high-fat diet. "
2.	Glucose Intolerance 05/01/2008 - "Oral glucose tolerance test showed that KRP-101 administration improved glucose intolerance. "
3.	Hyperinsulinism (Hyperinsulinemia) 05/01/2008 - "KRP-101 administration improved hyperglycemia and hyperinsulinemia as well as dyslipidemia in dogs fed a high-fat diet. "
4.	Hyperglycemia 05/01/2008 - "KRP-101 administration improved hyperglycemia and hyperinsulinemia as well as dyslipidemia in dogs fed a high-fat diet. "
5.	Hepatocellular Carcinoma (Hepatoma) 12/15/2007 - "To investigate the effect of PPARalpha agonism on mRNA expressions of lipid metabolism-related genes in human livers, a potent PPARalpha agonist, KRP-101 (KRP), was used to treat the human hepatoma cell line, HepaRG cells. "